About Diaxonhit
Diaxonhit is a company based in Paris (France) founded in 1997. Diaxonhit has raised $65.46 million across 7 funding rounds from investors including Danske Bank, BNP Paribas and HHS. Diaxonhit has completed 1 acquisition, including InGen. Diaxonhit operates in a competitive market with competitors including Abcam, Inscripta, Stem Cell Technologies, GenScript and OncoDNA, among others.
- Headquarter Paris, France
- SectorsHealthcare
- Email••••••••
- Website exonhit.com
- Social LinkedIn X Facebook
- Total Equity Funding$65.46M (USD)
in 7 rounds
- Latest Funding Round$2.4M (USD), Grant
Jun 2012
- InvestorsDanske Bank
& 8 more
- Investments & Acquisitions
Funding Insights of Diaxonhit
Diaxonhit has successfully raised a total of $65.46M across 7 strategic funding rounds. The most recent funding activity was a Grant round of $2.4 million completed in June 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $65.46M
- Total Rounds 7
- Last Round Grant — $2.4M
- First Round $12.4M
(Sep 2000)
- Investors Count 9
All 7 funding rounds of Diaxonhit with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2012 | $2.4M | Grant | – | – | – |
| Mar 2012 | $551,426 | Grant | – | – | |
| Dec 2010 | $300,000 | Grant | – | – | |
| Oct 2006 | $26.19M | Series C | – | – | – |
| Feb 2004 | $10.34M | Debt – Convertible | – | – | – |
| Dec 2001 | $26.87M | Series C | – | Danske Bank, Sofinnova Partners | – |
| Sep 2000 | $12.4M | Series B | – | Sofinnova Partners | – |
9 investors in total: 9 institutional.
Investors in Diaxonhit
Diaxonhit has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Danske Bank, BNP Paribas and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Life Sciences sector focused early stage VC firm investing primarily in Europe | – | sofinnova.fr | Paris, France | |
Early stage VC firm investing in the US and Korea | – | oxbio.com | Boston, United States | |
Diversified asset management, corporate advisory, and private equity firm focused on multiple sectors | 1953 | edmond-de-rothschild.com | Paris, France | |
Equity investments are provided to low and middle market companies. | 1997 | idinvest.com | Paris, France | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - | |
Financial services including banking and insurance are provided globally. | 1871 | danskebank.com | Copenhagen, Denmark | |
Banking & financial service provider | 1848 | group.bnpparibas | Paris, France | |
A blog on innovation and growth capital is provided. | 1996 | innovationcapital.fr | Paris, France |
Investor details for Diaxonhit
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Diaxonhit
Diaxonhit has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include InGen.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
IVD products for Infectious and autoimmune diseases | ingen.fr | Chilly Mazarin, France | 1993 | Nov 2012 | $23.05M |
Complete acquisition details for Diaxonhit
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Diaxonhit
4 dated milestones of Diaxonhit across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Diaxonhit is founded.
- Funding First funding round of $12.4M.
- Funding Latest funding round, Grant, of $2.4M.
- Acquisition Acquires InGen.
Competitors of Diaxonhit
Diaxonhit operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Abcam, Inscripta, Stem Cell Technologies, GenScript and OncoDNA, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| abcam.com | 1998 | Cambridge, United Kingdom | $78.8M | 405 | Biological reagents and antibodies are developed for life science research. | |
| inscripta.io | 2015 | Helsinki, Finland | $853,384 | – | Speech recognition solutions are provided by Inscripta for healthcare professionals. | |
| stemcell.com | 1993 | Vancouver, Canada | $11.92M | 129 | Developer of cell culture media and ancillary reagents for life science research | |
| genscript.com | 2002 | Piscataway, United States | $15M | 5,260 | Reagents and instruments are provided for life sciences research. | |
| oncodna.com | 2012 | Charleroi, Belgium | $44.53M | 37 | Genomic and theranostic services for oncology precision medicine are delivered. | |
| sinobiological.com | 2007 | Beijing, China | $29.41M | – | Reagents and kits are provided for clinical research applications. | |
| miltenyibiotec.com | 1989 | Bergisch Gladbach, Germany | – | 585 | Develops tools and products for research and clinical application | |
| diagenode.com | 2003 | Seraing, Belgium | $8.45M | 99 | Reagents and kits for epigenetics sequencing solutions are developed. | |
| fluentbio.com | 2018 | Watertown, United States | $19M | – | Proprietary reagents for single-cell genetic analysis are developed. | |
| devyser.com | 2004 | Stockholm, Sweden | $15.48M | – | Provider of molecular diagnostic kits for cancer, hereditary diseases, and reproductive disorders |
Detailed competitors of Diaxonhit
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Diaxonhit
Websites that share an audience with Diaxonhit (exonhit.com).
Websites whose visitors overlap most with Diaxonhit. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| hypromatrix.com | 87% | – | – | View details |
Similar companies to Diaxonhit
10 companies that operate in the same segment as Diaxonhit (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Diaxonhit
Diaxonhit was founded in 1997 and raised its 1st funding round 3 years after it was founded.
Diaxonhit is headquartered in Paris, France.
Diaxonhit is a funded company, having raised a total of $65.46M across 7 funding rounds to date. The company's 1st funding round was a Series B of $12.4M, raised on Sep 2000.
The Diaxonhit group is a fully integrated in-vitro diagnostics company with expertise ranging from discovery to commercialization of specialty diagnostic products. The company was a result of the acquisition of InGen BioSciences by Exonhit. Diaxonhit owns a broadened and diversified portfolio of proprietary diagnostic products in three specialty areas : transplantation, infectious diseases and cancer diagnosis. The group is currently marketing two proprietary products, TQS (Tetanus Quick Stick) for the evaluation of patients immune status against tetanus, and BJI Inoplex for the diagnosis of bone joint prosthetic infections. The group also commercializes AlloMap, a molecular test for the surveillance of heart-transplant patients, under an exclusive licence for Europe. Additionally, Diaxonhit develops other diagnostic products using its molecular biology platform, including Dx15, a molecular diagnostic test for thyroid cancer. Diaxonhits commercial affiliate, InGen, is currently the leading independent distributor of in vitro diagnostics in the French market. It markets specialty diagnostic tests to public and private clinical laboratories. InGen is the market leader in France for distribution of HLAs tests (Human Leukocyte Antigen) that assess the compatibility between donors and recipients for organ and bone marrow transplants, and enable surveillance of rejection after transplantation. InGen also distributes tests for European and American partners in the field of infectious diseases, auto-immunity and quality control products.
Diaxonhit's top competitors include Abcam, Sino Biological and OncoDNA.
Diaxonhit has made 1 acquisition, including InGen.
Diaxonhit has 9 investors. Key investors include Danske Bank, BNP Paribas, HHS, Edmond de Rothschild, and Idinvest Partners.